VENUS CONCEPT INC (VERO)
US92332W2044 - Common Stock
We assign a fundamental rating of 1 out of 10 to VERO. VERO was compared to 188 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of VERO have multiple concerns. VERO does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year VERO has reported negative net income.
VERO had a negative operating cash flow in the past year.
VERO had negative earnings in each of the past 5 years.
VERO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
VERO has a worse Return On Assets (-69.38%) than 75.94% of its industry peers.
VERO has a worse Return On Equity (-496.11%) than 88.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -69.38% | ||
| ROE | -496.11% | ||
| ROIC | N/A |
ROA(3y)-29.74%
ROA(5y)-32.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of VERO (67.68%) is better than 74.87% of its industry peers.
In the last couple of years the Gross Margin of VERO has grown nicely.
The Profit Margin and Operating Margin are not available for VERO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 67.68% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.21%
GM growth 5Y9.61%
2. Health
2.1 Basic Checks
VERO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VERO has more shares outstanding
Compared to 5 years ago, VERO has more shares outstanding
Compared to 1 year ago, VERO has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -5.77, we must say that VERO is in the distress zone and has some risk of bankruptcy.
VERO has a worse Altman-Z score (-5.77) than 70.05% of its industry peers.
A Debt/Equity ratio of 3.40 is on the high side and indicates that VERO has dependencies on debt financing.
VERO has a worse Debt to Equity ratio (3.40) than 87.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.4 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.77 |
ROIC/WACCN/A
WACC4.93%
2.3 Liquidity
A Current Ratio of 1.86 indicates that VERO should not have too much problems paying its short term obligations.
VERO has a worse Current ratio (1.86) than 71.66% of its industry peers.
VERO has a Quick Ratio of 1.18. This is a normal value and indicates that VERO is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of VERO (1.18) is worse than 71.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.86 | ||
| Quick Ratio | 1.18 |
3. Growth
3.1 Past
The earnings per share for VERO have decreased strongly by -15.56% in the last year.
Looking at the last year, VERO shows a very negative growth in Revenue. The Revenue has decreased by -18.57% in the last year.
VERO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 28.26% yearly.
EPS 1Y (TTM)-15.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.95%
Revenue 1Y (TTM)-18.57%
Revenue growth 3Y-0.71%
Revenue growth 5Y28.26%
Sales Q2Q%-14.79%
3.2 Future
Based on estimates for the next years, VERO will show a very strong growth in Earnings Per Share. The EPS will grow by 22.06% on average per year.
VERO is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.14% yearly.
EPS Next Y-2.82%
EPS Next 2Y28.89%
EPS Next 3Y22.06%
EPS Next 5YN/A
Revenue Next Year-13.52%
Revenue Next 2Y-3.55%
Revenue Next 3Y-0.14%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for VERO. In the last year negative earnings were reported.
Also next year VERO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
VERO's earnings are expected to grow with 22.06% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.89%
EPS Next 3Y22.06%
5. Dividend
5.1 Amount
VERO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VENUS CONCEPT INC
NASDAQ:VERO (11/22/2024, 8:11:23 PM)
After market: 0.3698 +0.04 (+13.78%)0.325
+0.04 (+12.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.36M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -69.38% | ||
| ROE | -496.11% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 67.68% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.93
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.4 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.86 | ||
| Quick Ratio | 1.18 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-15.56%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-2.82%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-18.57%
Revenue growth 3Y-0.71%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y